Krystal Biotech, Inc. (KRYS) - Cash per Share

Krystal Biotech, Inc. (KRYS) relies moderately on external researchers while keeping drug production in-house. The cash per share trend on the GURU.Markets chart confirms this trajectory, where 30.77 represents the latest level. This supports a unique gene delivery system for skin treatment and ensures the stable operation of a modern GMP plant with optimal capacity utilization.
Comprehensive metric breakdowns and analytics for Krystal Biotech Inc (KRYS)

This metric determines the volume of liquid cash per common share, allowing for an assessment of the financial safety cushion and capital allocation efficiency without accounting for reporting lags. This cash reserve per share chart confirms the ability of Krystal Biotech, Inc. (KRYS) to fund the aggressive scaling of gene therapy distribution and the launch of new ophthalmology studies without the risk of cash flow gaps.